The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).
 
Lizza Hendriks
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst)
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Clemence Henon
No Relationships to Disclose
 
Laura Mezquita
No Relationships to Disclose
 
Edouard Auclin
No Relationships to Disclose
 
Roberto Ferrara
No Relationships to Disclose
 
Clarisse Audigier-Valette
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sysmex
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Msd (Inst); Novartis (Inst); Pfizer (Inst); Roche; Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
 
Cecile Le Pechoux
Consulting or Advisory Role - AstraZeneca
 
Angela Botticella
No Relationships to Disclose
 
Samy Ammari
No Relationships to Disclose
 
Anas Gazzah
No Relationships to Disclose
 
Caroline Caramella
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer
 
Julien Adam
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
Research Funding - Merck Sharp & Dohme (Inst); Pierre Fabre (Inst); Sanofi (Inst)
 
David Planchard
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD Oncology; Novartis; Pfizer; Roche
 
Anne-Marie C. Dingemans
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Inivata (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); OncoMed (Inst); Onxeo (Inst); ose pharma (Inst); ose pharma (Inst); Pfizer (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche